EliyahuKhankinMD, FASN, FAST(He/Him)

Kidney & Pancreas Transplantation

Assistant Professor of Medicine, Harvard Medical School. Director, Clinical Research, Transplant Institute. Director, Transplant Institute Biorepository (T. I. B. R.). Beth Israel Deaconess Medical Center, Boston MA.

Join to view full profile

Dr. Khankin is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Khankin's full profile

Already have an account?

Office
330 Brookline Ave
Boston, MA 02215
Phone+1 617-667-7000

Fax+1 617-667-3626

Summary

Dr. Eliyahu Khankin is a nephrologist in Boston, MA and is affiliated with Beth Israel Deaconess Medical Center. He received his medical degree from Technion-Israel Inst of Technology Faculty of Medicine and has been in practice 14 years. He also speaks multiple languages, including Russian and Hebrew. He specializes in kidney & pancreas transplantation and is experienced in hypertension, acute renal failure, transplant nephrology, glomerular disease, and dialysis.

Education & Training

Beth Israel Deaconess Medical CenterFellowship, Nephrology, 2013 - 2014
Beth Israel Deaconess Medical CenterFellowship, Nephrology, 2011 - 2013
Technion-Israel Inst of Technology Faculty of MedicineClass of 2002

Certifications & Licensure

MA State Medical License 2013 - 2026

Awards, Honors, & Recognition

Fellow of American Society of Transplantation (FAST) American Society of Transplantation, 2019
Fellow of American Society of Nephrology (FASN) American Society of Nephrology, 2008

Clinical Trials

Prevention of Delayed Graft Function Using Eculizumab Therapy (PROTECT Study) Start of enrollment: 2014 Aug 21
Completed
Phase 2, Phase 3
Evaluation of Patient Outcomes From the Kidney Allograft Outcomes AlloSure Registry Start of enrollment: 2018 Jan 23
Active, not recruiting
Clazakizumab for the Treatment of Chronic Active Antibody Mediated Rejection in Kidney Transplant Recipients Start of enrollment: 2019 Oct 14
Terminated
Phase 3
Phase III Study Assessing the Efficacy and Safety of Pegcetacoplan in Patients With C3 Glomerulopathy or Immune-Complex Membranoproliferative Glomerulonephritis Start of enrollment: 2021 Nov 12
Active, not recruiting
Phase 3
An Open-Label, Nonrandomized, Multicenter Extension Study to Evaluate the Long-term Safety and Efficacy of Pegcetacoplan in Participants With C3 Glomerulopathy or Immune-Complex Membranoproliferative Glomerulonephritis Start of enrollment: 2023 May 29
Active, not recruiting
Phase 3
Join now to see all

Publications & Presentations

PubMed

365 citations
Cardiac angiogenic imbalance leads to peripartum cardiomyopathy
Ian S. Patten, Sarosh Rana, Sajid Shahul, Glenn C. Rowe, Cholsoon Jang
Nature. 2012-05-17
62 citations
Exposure to Experimental Preeclampsia in Mice Enhances the Vascular Response to Future Injury
Dafina Pruthi, Eliyahu V. Khankin, Robert M. Blanton, Mark Aronovitz, Suzanne D. Burke
Hypertension. 2015-04-01
339 citations
PGC1α drives NAD biosynthesis linking oxidative metabolism to renal protection
Mei T. Tran, Zsuzsanna K. Zsengellér, Anders H. Berg, Eliyahu V. Khankin, Manoj Bhasin
Nature. 2016-03-24

Journal Articles

Cytomegalovirus Mismatch Still Negatively Affects Patient and Graft Survival in the Era of Routine Prophylactic and Preemptive Therapy: A Paired Kidney Analysis
E V Khankin, F Cardarelli, M Pavlakis, N Leeaphorn, American journal of transplantation